Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. In a phase 1...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Walker, Alison R., Marcucci, Guido, Yin, Jun, Blum, William, Stock, Wendy, Kohlschmidt, Jessica, Mrózek, Krzysztof, Carroll, Andrew J., Eisfeld, Ann-Kathrin, Wang, Eunice S., Jacobson, Sawyer, Kolitz, Jonathan E., Thakuri, Mohan, Sutamtewagul, Grerk, Vij, Ravi, Stuart, Robert K., Byrd, John C., Bloomfield, Clara D., Stone, Richard M., Larson, Richard A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2021
Soggetti:
Clinical Trials and Observations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8288671/
https://ncbi.nlm.nih.gov/pubmed/34251414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004233
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi